Discover how AI-powered lab-in-the-loop techniques are revolutionizing drug discovery by identifying and validating novel therapeutic targets. This presentation explores how our platform enables pharmaceutical partners to query real-world data for patients predicted to respond to inhibition of entirely new targets and early-stage developmental assets—even those not yet in clinical trials. Learn how this approach accelerates target validation and patient stratification, bridging the gap between computational prediction and clinical reality.

This session unveils updated insights from the landmark ‘Practice Gap’ study tracking how personalized medicine is implemented in advanced non-small cell lung cancer. Building on the seven-step clinical practice gap framework, the latest analysis from Diaceutics uses new data to reveal where progress has been made—and where gaps persist—over the past four years. Attendees will gain a forward-looking view of emerging trends and the challenges still shaping precision oncology.

Foundation models trained on single-cell, perturbation, multimodal, and spatial data are beginning to close the gap between high-resolution profiling and biological interpretation. They turn tumor measurements into reusable cell-state predictions across discovery, patient stratification, and clinical workflows. Early proof points exist, capital is flowing, and pharma adoption playbooks are emerging. Differentiated data, workflow fit, credible validation will matter as much as model architecture in deciding who leads.

Early cancer discovery is challenging due to heterogeneity of different cancers and even within cancers from the same organ. Freenome built a multiomics discovery platform that looks for signals along the entire central dogma—DNA, methylation, RNA, protein, immunoprofiling, extracellular vesicles, circulating cells, among others. During this talk, we will discuss clinical, scientific, and computational strategies that are critical to create the best products to benefit patients.

In hepatocyte-derived extracellular vesicles from blood, core liver-cancer hallmarks emerge across the disease continuum, including hypoxia, ferroptosis, and metabolic rewiring, invisible in matched bulk. Same vesicles, multiple omic layers, one tissue source. Deconvolution recovers tissue identity for one analyte class today; extending it across omic layers is gated by reference cohorts and analytical tooling that do not exist. Tissue-specific EVs (TS-EVs) skip the inference step: tissue identity travels with the vesicle. The platform underpins EvoLiver (FDA Breakthrough, HCC surveillance) and a precision-medicine partnership with a leading global pharma in MASH.

Diana Abdueva, co-founder and CEO of Aqtual, will discuss how liquid biopsy, active chromatin cell-free DNA (cfDNA), and advanced biomarker analysis are expanding precision medicine beyond oncology into chronic and autoimmune diseases. She will highlight how transcriptomic, epigenetic, and protein-DNA signals from a simple blood draw can guide therapy selection, improve patient outcomes, and enable companion diagnostics.

MRD is becoming increasingly embedded in routine care across solid and hematologic cancers. This talk provides an overview of where MRD is gaining traction across tumor types and intervention points along the patient journey, spanning perioperative through surveillance settings. It will also outline key assay modalities (NGS, PCR, flow, etc.) and technology approaches (tumor-informed vs tumor-naïve) and highlight how MRD is shaping therapeutic development and trial design.

Liquid biopsy is transforming cancer diagnosis and treatment decision-making. Yet, adoption remains fragmented across disease- and treatment-specific settings. As next-generation platforms emerge with pan-tumor, longitudinal capabilities, the focus shifts toward continuous cancer management. This session highlights evolving market dynamics and how scalable liquid biopsy solutions could transform care from early detection through long-term monitoring.

Nutrition impacts all aspects of health and longevity, yet the responses to food are highly personalized. Using Continuous Glucose Monitoring (CGM) we demonstrate that individuals have personalized glucose responses to different carbohydrates. We further show that individuals have different subtypes of glucose dysregulation (e.g. muscle insulin resistance, beta cell defect, incretin effects) and that the response and mitigation of the postprandial response depends upon the dysregulation subtype. Association of lifestyle including food, activity, and timing are correlated with glucose levels. This information enables personalized management of glucose dysregulation.

Biomarkers to inform clinical decisions in non-oncology indications such as Alzhiemer's, Parkinson's Disease and metabolic disorders are becoming increasingly important. These conditions are unique from oncology which presents numerous opportunities, as well as a number of challenges. This talk will focus on trends in the use of biomarkers, key challenges and a call to action for industry stakeholders.

The convergence of AI and epigenetics is redefining what’s possible in cardiovascular medicine. Using AI, it is now possible to decode the dynamic molecular changes that reflect lifestyle impact alongside genetics to enable a new frontier in highly personalized prediction, prevention, and management of heart disease. This presentation will explore how the fusion of AI and epigenetics is delivering actionable intelligence for truly individualized cardiovascular prevention, diagnosis, and care optimization.

Steve Gardner will outline how AI-led combinatorial analytics is enabling a preventative approach to complex chronic diseases. By determining lifetime risk of disease; predicting individual response to treatments, including GLP-1s; and systematically identifying disease-resilient protective genes linked to healthier aging and resistance to neurodegeneration; PrecisionLife is demonstrating how mechanistic insights will power the revolution of proactive, personalized, and preventative care.

Precision medicine's next frontier beyond oncology. Octave Bioscience CEO Doug Biehn shares how precision neurology is advancing the field and patient care. Octave’s category defining platform shifts neurodegenerative care from subjective symptom management to objective biological measurement. By applying AI enabled multivariate biomarkers to Multiple Sclerosis and Parkinson’s Disease, Octave delivers clinically actionable insights that optimize treatment and establish precision neurology as the new standard of care.

Large-scale genetic and genomic datasets have transformed the study of complex diseases, yet heterogeneity across studies and the difficulty of translating statistical associations into biological insight limit their utility. Polygenic risk scores (PGS), widely used to quantify genetic risk for conditions such as Alzheimer’s disease (AD), exemplify these challenges. Here, we present BrainGeneBot, a GPT-driven chat framework designed to connect complex genetic data with biologically meaningful interpretation.